Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm

Holmes Chapel, UK, and Stockholm, Sweden; Tuesday 2nd April 2024 - Today, Bespak announced the completion of its spin-out from Recipharm to form a new standalone organisation focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.

Chris Hirst, CEO Bespak, said: "The spin-out of three former Recipharm sites, each with a long history in inhaled and nasal drug delivery, creates a new company with a clear vision and a unique offering for customers. The new Bespak will be the trusted innovation partner and sustainability leader in the transition to greener inhalers."

Greg Behar, CEO Recipharm added: "Today's announcement reinforces Recipharm's dedication to driving growth and fostering innovation within our core segments: OSD, SFF and Biologics. As a new chapter opens in Bespak's development, I would like to take this opportunity to wish Chris Hirst and the whole Bespak team all the best for a prosperous future filled with accomplishments and breakthroughs."

For more information, please see Bespak's press release